Literature DB >> 22970693

Surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2009-2010.

Dale R Burwen1, Sukhminder K Sandhu, Thomas E MaCurdy, Jeffrey A Kelman, Jonathan M Gibbs, Bruno Garcia, Marianthi Markatou, Richard A Forshee, Hector S Izurieta, Robert Ball.   

Abstract

OBJECTIVES: We implemented active surveillance for Guillain-Barré syndrome (GBS) following seasonal or H1N1 influenza vaccination among the Medicare population during the 2009-2010 influenza season.
METHODS: We used weekly Medicare claims data to monitor vaccinations and subsequent hospitalizations with principal diagnosis code for GBS within 42 days. Group sequential testing assessed whether the observed GBS rate exceeded a critical limit based on the expected rate from 5 previous years adjusted for claims delay. We evaluated the lag between date of service and date of claims availability and used it for adjustment.
RESULTS: By July 30, 2010 (after 26 interim surveillance tests), 14.0 million seasonal and 3.3 million H1N1 vaccinations had accrued. Taking into account claims delay appropriately lowered the critical limit during early monitoring. The observed GBS rate was below the critical limit throughout the surveillance.
CONCLUSIONS: Medicare data contributed rapid safety monitoring among millions of 2009-2010 influenza vaccine recipients. Adjustment for claims delay facilitates early detection of potential safety issues. Although limited by lack of medical record review to confirm cases, this claims-based surveillance did not indicate a statistically significant elevated GBS rate following seasonal or H1N1 influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22970693      PMCID: PMC3490645          DOI: 10.2105/AJPH.2011.300510

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  20 in total

1.  Active surveillance of vaccine safety: a system to detect early signs of adverse events.

Authors:  Robert L Davis; Margarette Kolczak; Edwin Lewis; James Nordin; Michael Goodman; David K Shay; Richard Platt; Steven Black; Henry Shinefield; Robert T Chen
Journal:  Epidemiology       Date:  2005-05       Impact factor: 4.822

2.  Real-time vaccine safety surveillance for the early detection of adverse events.

Authors:  Tracy A Lieu; Martin Kulldorff; Robert L Davis; Edwin M Lewis; Eric Weintraub; Katherine Yih; Ruihua Yin; Jeffrey S Brown; Richard Platt
Journal:  Med Care       Date:  2007-10       Impact factor: 2.983

3.  Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group.

Authors:  T J Safranek; D N Lawrence; L T Kurland; D H Culver; W C Wiederholt; N S Hayner; M T Osterholm; P O'Brien; J M Hughes
Journal:  Am J Epidemiol       Date:  1991-05-01       Impact factor: 4.897

4.  The Vaccine Safety Datalink project.

Authors:  F DeStefano
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Aug-Sep       Impact factor: 2.890

5.  An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines.

Authors:  A D Langmuir; D J Bregman; L T Kurland; N Nathanson; M Victor
Journal:  Am J Epidemiol       Date:  1984-06       Impact factor: 4.897

6.  Evaluation of Guillain-Barré Syndrome among recipients of influenza vaccine in 2000 and 2001.

Authors:  Dale R Burwen; Robert Ball; Wilson W Bryan; Hector S Izurieta; Lawrence La Voie; Neville A Gibbs; Rebecca Kliman; M Miles Braun
Journal:  Am J Prev Med       Date:  2010-10       Impact factor: 5.043

7.  Evaluating adverse events after vaccination in the Medicare population.

Authors:  Dale R Burwen; Lawrence La Voie; M Miles Braun; Peter Houck; Robert Ball
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-07       Impact factor: 2.890

8.  The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

Authors:  T Lasky; G J Terracciano; L Magder; C L Koski; M Ballesteros; D Nash; S Clark; P Haber; P D Stolley; L B Schonberger; R T Chen
Journal:  N Engl J Med       Date:  1998-12-17       Impact factor: 91.245

9.  Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome.

Authors:  Irving Nachamkin; Sean V Shadomy; Anthony P Moran; Nancy Cox; Collette Fitzgerald; Huong Ung; Adrian T Corcoran; John K Iskander; Lawrence B Schonberger; Robert T Chen
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

10.  Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977.

Authors:  L B Schonberger; D J Bregman; J Z Sullivan-Bolyai; R A Keenlyside; D W Ziegler; H F Retailliau; D L Eddins; J A Bryan
Journal:  Am J Epidemiol       Date:  1979-08       Impact factor: 4.897

View more
  11 in total

1.  Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.

Authors:  Rohit P Ojha; Bradford E Jackson; Joseph E Tota; Tabatha N Offutt-Powell; Karan P Singh; Sejong Bae
Journal:  Hum Vaccin Immunother       Date:  2013-09-06       Impact factor: 3.452

2.  Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.

Authors:  Hector S Izurieta; Nicole Thadani; David K Shay; Yun Lu; Aaron Maurer; Ivo M Foppa; Riley Franks; Douglas Pratt; Richard A Forshee; Thomas MaCurdy; Chris Worrall; Andrew E Howery; Jeffrey Kelman
Journal:  Lancet Infect Dis       Date:  2015-02-09       Impact factor: 25.071

3.  Continuous Post-Market Sequential Safety Surveillance with Minimum Events to Signal.

Authors:  Martin Kulldorff; Ivair R Silva
Journal:  Revstat Stat J       Date:  2017-07       Impact factor: 0.985

4.  Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.

Authors:  Barbara H Bardenheier; Susan K Duderstadt; Renata J M Engler; Michael M McNeil
Journal:  Vaccine       Date:  2016-07-19       Impact factor: 3.641

5.  Guillain-Barré syndrome and antecedent cytomegalovirus infection, USA 2009-2015.

Authors:  Jessica Leung; James J Sejvar; Jesus Soares; Tatiana M Lanzieri
Journal:  Neurol Sci       Date:  2019-12-11       Impact factor: 3.307

Review 6.  Influenza vaccines: Evaluation of the safety profile.

Authors:  Claudia Maria Trombetta; Elena Gianchecchi; Emanuele Montomoli
Journal:  Hum Vaccin Immunother       Date:  2018-01-30       Impact factor: 3.452

7.  Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems.

Authors:  Paolo Pellegrino; Carla Carnovale; Valentina Perrone; Marco Pozzi; Stefania Antoniazzi; Emilio Clementi; Sonia Radice
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

8.  Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database.

Authors:  Enrique Alcalde-Cabero; Javier Almazán-Isla; Fernando J García López; José Ramón Ara-Callizo; Fuencisla Avellanal; Carlos Casasnovas; Carlos Cemillán; José Ignacio Cuadrado; Jacinto Duarte; María Dolores Fernández-Pérez; Óscar Fernández; Juan Antonio García Merino; Rosa García Montero; Dolores Montero; Julio Pardo; Francisco Javier Rodríguez-Rivera; María Ruiz-Tovar; Jesús de Pedro-Cuesta
Journal:  BMC Neurol       Date:  2016-05-21       Impact factor: 2.474

Review 9.  Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methods.

Authors:  Andreia Leite; Nick J Andrews; Sara L Thomas
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-28       Impact factor: 2.890

10.  Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System.

Authors:  Weiling Katherine Yih; Martin Kulldorff; Sukhminder K Sandhu; Lauren Zichittella; Judith C Maro; David V Cole; Robert Jin; Alison Tse Kawai; Meghan A Baker; Chunfu Liu; Cheryl N McMahill-Walraven; Mano S Selvan; Richard Platt; Michael D Nguyen; Grace M Lee
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-11-17       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.